#14: Citius Oncology's LYMPHIR™ Launch Strategy

Citius Oncology is preparing to launch LYMPHIR™, a novel treatment for cutaneous T-cell lymphoma (CTCL), and is simultaneously exploring strategic options to maximize its market impact. These options include partnerships and acquisitions to bolster its position within the $400 million CTCL market. The company is focusing on a targeted launch strategy that includes patient support programs and securing international licensing agreements. Their aim is to provide patients with a much-needed therapy while increasing shareholder value. This launch follows years of development and regulatory hurdles. Hosted on Acast. See acast.com/privacy for more information.